Comment by mlyle

The deal is supposed to be that there's a trade:

* You are given an exclusive right to exploit a work, for enough time to make it worth your while.

* Everyone gets the work in the end.

We're not succeeding at this. The terms are a little too short for biotech. They're wayyyyy too long for software. The barriers to entry to get and enforce IP are too large for small businesses. But it's also too easy to figure it all out and generate tons of fake IPR to harass real business with.